This Article Full Text Full Text (PDF) All Versions of this Article: 34/12/2975    most recent 01.STR.0000101914.62066.7Bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gautier, S. Articles by Bordet, R. Search for Related Content PubMed PubMed Citation Articles by Gautier, S. Articles by Bordet, R. Pubmed/NCBI databases Substance via MeSH Related Collections Animal models of human disease Acute Cerebral Infarction Intracerebral Hemorrhage Thrombolysis Endothelium/vascular type/nitric oxide

(Stroke. 2003;34:2975.)
© 2003 American Heart Association, Inc.

Original Contributions

Involvement of Thrombolysis in Recombinant Tissue Plasminogen Activator-Induced Cerebral Hemorrhages and Effect on Infarct Volume and Postischemic Endothelial Function

Sophie Gautier, PharmD; Olivier Petrault; Patrick Gele; Maud Laprais; Michelle Bastide, PhD; Anne Bauters, MD; Dominique Deplanque, MD, PhD; Brigitte Jude, MD, PhD; Jacques Caron, MD Régis Bordet, MD, PhD

From the Laboratoire de Pharmacologie, Faculté de Medecine, Lille, France.

Correspondence to R. Bordet, Laboratoire de Pharmacologie, Faculté de Médecine, 1 place de Verdun, 59045 Lille cedex, France. E-mail bordet{at}univ-lille2.fr

Background and Purpose— In a model of mechanical focal ischemia, we investigated the involvement of thrombolysis products (TLP) in recombinant tissue plasminogen activator (rtPA)-induced intracerebral complications and the effects on infarct volume and postischemic endothelial function.

Methods— Hemorrhage incidence and severity were evaluated by histomorphometric analysis in male spontaneously hypertensive rats (SHR) subjected to 60-minute intraluminal middle cerebral artery (MCA) occlusion and receiving intravenously 5 hours later either saline, rtPA (3, 10, or 30 mg/kg), or rtPA (10 mg/kg) associated with TLP (rtPA+TLP). In addition, MCA reactivity was assessed in rtPA- or rtPA+TLP-treated SHR versus control Wistar-Kyoto rats or SHR.

Results— No hemorrhage was observed visually in SHR receiving saline. In contrast, rtPA administration induced hemorrhagic complications in infarcted areas in a dose-independent manner. Administration of rtPA+TLP solution, containing a high concentration of plasmin, did not affect hemorrhage incidence but significantly increased hemorrhage severity (8.8±2.3 petechiae versus 3.0±1.0 petechiae in rtPA group; P<0.001). This increased severity was associated with a significant increase of both infarct volume (182±10 versus 144±15 mm³ in rtPA group; P<0.01) and postischemic impairment of MCA endothelium-dependent relaxation (9±0.5% versus 13±1% in rtPA group; P<0.05).

Conclusions— Treatment with rtPA led to intracerebral hemorrhages, in contrast to saline-treated animals, and the presence of TLP increased the severity of these hemorrhages, in parallel with increased infarct volume and worsened endothelial function.

Key Words: hemorrhage • ischemia, focal • plasmin • thrombolysis • tissue plasminogen activator

This article has been cited by other articles:

				E. C. Henning, L. L. Latour, J. M. Hallenbeck, and S. Warach Reperfusion-Associated Hemorrhagic Transformation in SHR Rats: Evidence of Symptomatic Parenchymal Hematoma Stroke, December 1, 2008; 39(12): 3405 - 3410. [Abstract] [Full Text] [PDF]

				L Derex and N Nighoghossian Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1093 - 1099. [Abstract] [Full Text] [PDF]

				D. J. Schneider and B. E. Sobel A Novel Role for Tissue-Type Plasminogen Activator: Prevention of Thromboembolic Occlusion Circulation, September 30, 2008; 118(14): 1408 - 1409. [Full Text] [PDF]

				C. Rottger, K. Madlener, M. Heil, T. Gerriets, M. Walberer, T. Wessels, G. Bachmann, M. Kaps, and E. Stolz Is Heparin Treatment the Optimal Management for Cerebral Venous Thrombosis?: Effect of Abciximab, Recombinant Tissue Plasminogen Activator, and Enoxaparin in Experimentally Induced Superior Sagittal Sinus Thrombosis Stroke, April 1, 2005; 36(4): 841 - 846. [Abstract] [Full Text] [PDF]